Ftse Mib
34.242,49
0,75%
DAX
18.430,05
1,42%
S&P 500
5.187,70
0,13%
NASDAQ
16.332,56
-0,10%
Bitcoin
62.739,53
0,65%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Impel Pharmaceuticals Inc (IMPL) Impel Pharmaceuticals Inc (IMPL) Notizie

IMPL

Impel Pharmaceuticals (IMPL)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IMPL
DataOraFonteTitoloSimboloCompagnia
09/04/202422:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMPLImpel Pharmaceuticals Inc
16/02/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IMPLImpel Pharmaceuticals Inc
14/02/202423:21Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:IMPLImpel Pharmaceuticals Inc
14/02/202423:16Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:IMPLImpel Pharmaceuticals Inc
14/02/202423:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMPLImpel Pharmaceuticals Inc
26/12/202322:32Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IMPLImpel Pharmaceuticals Inc
05/10/202323:19Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IMPLImpel Pharmaceuticals Inc
05/10/202314:00GlobeNewswire Inc.Impel Pharmaceuticals Announces Exploration of Strategic AlternativesNASDAQ:IMPLImpel Pharmaceuticals Inc
18/08/202315:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMPLImpel Pharmaceuticals Inc
15/08/202322:29Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:IMPLImpel Pharmaceuticals Inc
05/07/202316:05AllPennyStocks.comBiotech Catches Major Premarket BidNASDAQ:IMPLImpel Pharmaceuticals Inc
21/06/202312:00Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:IMPLImpel Pharmaceuticals Inc
15/06/202314:00GlobeNewswire Inc.Impel Pharmaceuticals to Present New Real-World Data for Trudhesa® at the 65th Annual Scientific Meeting of the American Headache SocietyNASDAQ:IMPLImpel Pharmaceuticals Inc
12/05/202322:23Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:IMPLImpel Pharmaceuticals Inc
12/05/202317:23Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:IMPLImpel Pharmaceuticals Inc
12/05/202314:00GlobeNewswire Inc.Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:IMPLImpel Pharmaceuticals Inc
10/05/202314:11Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:IMPLImpel Pharmaceuticals Inc
10/05/202314:00GlobeNewswire Inc.Impel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial OfficerNASDAQ:IMPLImpel Pharmaceuticals Inc
05/05/202314:00GlobeNewswire Inc.Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023NASDAQ:IMPLImpel Pharmaceuticals Inc
27/04/202322:10Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:IMPLImpel Pharmaceuticals Inc
27/04/202322:09Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:IMPLImpel Pharmaceuticals Inc
26/04/202314:00GlobeNewswire Inc.Impel Pharmaceuticals Presents New Data at AAN 2023 Suggesting Trudhesa® Nasal Spray is Safe to Use When Co-Administered With Commonly Prescribed Migraine MedicationsNASDAQ:IMPLImpel Pharmaceuticals Inc
14/04/202322:12Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:IMPLImpel Pharmaceuticals Inc
12/04/202322:01GlobeNewswire Inc.Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of DirectorsNASDAQ:IMPLImpel Pharmaceuticals Inc
11/04/202314:00GlobeNewswire Inc.Impel Pharmaceuticals to Present Data on Trudhesa® Nasal Spray for Treatment of Acute Migraine at 2023 American Academy of Neurology Annual MeetingNASDAQ:IMPLImpel Pharmaceuticals Inc
31/03/202322:32Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:IMPLImpel Pharmaceuticals Inc
24/03/202313:17GlobeNewswire Inc.Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateNASDAQ:IMPLImpel Pharmaceuticals Inc
17/03/202313:00GlobeNewswire Inc.Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023NASDAQ:IMPLImpel Pharmaceuticals Inc
03/03/202322:01GlobeNewswire Inc.Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in MarchNASDAQ:IMPLImpel Pharmaceuticals Inc
22/02/202322:30GlobeNewswire Inc.Impel Pharmaceuticals Announces Strategic Repriortization, Continues Focus on Maximizing Trudhesa® Commercial OpportunityNASDAQ:IMPLImpel Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IMPL

La tua Cronologia

BIT
RACE
Ferrari NV
BIT
UCG
Unicredit
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
ISP
Intesa Sanpaolo
BIT
CPR
Davide Campari
BIT
STMMI
ST Microelectronics
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
LDO
Leonardo
BIT
FBK
Finecobank
BIT
ENI
Eni
BIT
IRE
Iren
BIT
G
Generali
BIT
SRG
Snam
BIT
BAMI
Banco BPM
BIT
BPE
Bper Banca
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network